$BRKR

Munch Mark sold $115K of BRKR

Munch Mark (EXEC VP&PRES BRUKER NANO INC.) sold 2,000 shares of BRUKER CORP (BRKR) at $57.60 ($0.12M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Munch Mark
Published Aug 18, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BRKR
Neutral
medium confidence
Mentioned
$BRKR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BRKRNeutralLow
01

Why it matters

This is a disclosed open-market sale by an executive under a pre-arranged 10b5-1 plan; it is generally more sentiment-relevant than fundamentals-relevant.

02

Market read

Traders may log the transaction for sentiment monitoring, but there is no new operational or financial information in the text.

03

What to watch

The sale size ($115.2k) is modest relative to typical market-moving thresholds, and the 10b5-1 structure suggests the timing was predetermined rather than information-driven.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed after-hours on 2026-08-18

Background

The article is an SEC Form 4 insider transaction disclosure for Bruker Corp (BRKR).

Company-level read

Ticker impact

$BRKRNeutralMedium confidence
Context

Bruker Corp Form 4 shows exec VP and Pres Bruker Nano, Munch Mark, sold 2,000 shares at $57.60 on 2026-08-14 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as this is a single-company insider transaction without guidance, contracts, or regulatory developments.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution about near-term performance, so traders may still watch for follow-on disclosures.

Key entities

  • BRUKER CORP

    Subject of the Form 4 insider transaction disclosure.

  • Munch Mark

    Executive VP and Pres, Bruker Nano, reported an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BRKRMed

J.P. Morgan Downgrades Bruker Corporation (BRKR) to Neutral Amid

J.P. Morgan downgraded Bruker Corporation (BRKR) to Neutral with a $70 price target, citing concerns about its Academia & Government segment and uncertain revenue growth. Bruker's P/S ratio is 2.45x, below its historical median and industry average. The company has a GF Score of 84/100, with strengths in valuation and momentum, but faces insider selling and mixed institutional interest.

$BRKRMed

Bruker, Sotera downgraded as J.P. Morgan reviews life sciences coverage

J.P. Morgan downgraded Bruker (BRKR) to Neutral and Sotera Health (SHC) to Underweight, citing uncertainty in their respective markets. Analyst Casey Woodring maintained a $70 price target for Bruker but expressed concerns about its exposure to lagging segments. For Sotera, Woodring lowered the price target to $17 from $18, citing underperformance tied to its medtech client base.

$BRKRMed

BRKR Stock Slides As Fusion Deal Collides With UBS Reality Check

Bruker Corporation (BRKR) stock rose 7.62% after strong earnings and guidance. The company's BEST unit partnered with Luvata for superconducting wire production, tying it to fusion and high-field magnet projects. UBS raised its price target to $65 but maintained a Neutral rating, citing mixed growth prospects. BRKR's revenue is $3.44B, but it reported a net loss of $52M and negative free cash flow.

$BRKRMed

BRKR Stock Pulls Back As Fusion Bet And UBS Target Collide

Bruker Corporation (BRKR) stock rose 7.66% on September 16, 2026, driven by positive coverage of its scientific instruments and fusion-related advancements. The company's stock has climbed from the mid-$56s to around $60, with recent closes near $60.02. Bruker's revenue is $3.44B with a 46.4% gross margin, but it reported a quarterly net loss of $52M. UBS initiated coverage with a Neutral rating and a $65 price target, citing optimism around fusion technology and AI-linked semiconductor demand.